At a Glance

Why It's Ordered
Cardiovascular risk stratification and lipid-lowering therapy decisions, and evaluation of very high triglycerides (pancreatitis risk) or suspected familial hypercholesterolemia. Not an emergency test; it does not diagnose acute coronary syndrome.
Check First
Triglycerides (pancreatitis risk at ≥1,000 mg/dL), LDL-C (ASCVD risk and treatment target), and non-HDL-C (best single marker when triglycerides are high).
Critical Values
TG ≥1,000 mg/dL (urgent: pancreatitis risk) · LDL-C ≥190 mg/dL (FH evaluation and high-intensity statin threshold) · Total cholesterol ≥300 mg/dL (rough FH flag). LDL-C and total cholesterol are not laboratory critical calls.
Don't Miss
Triglycerides ≥1,000 mg/dL with abdominal pain: treat as pancreatitis and check lipase. Lipemic samples can also distort results; ask the lab to verify before acting on a surprising value.
Field & Transport
Lipid testing is laboratory-only; no point-of-care lipid test is standard in EMS or transport. Do not delay transfer for results. Request the most recent lipid values and any statin, fibrate or omega-3 history from the sending facility.

Panel Overview

The Lipid Panel measures the fats in blood that drive atherosclerosis. The standard panel reports 5 values: total cholesterol, HDL-C and triglycerides (measured), and LDL-C and non-HDL-C (calculated, or LDL-C measured directly when triglycerides are high). It is the main test for estimating cardiovascular risk and for deciding on statins and other lipid-lowering drugs.

In acute care it is rarely the test that changes management in the first hour. Its main emergency role is very high triglycerides, which can cause pancreatitis. Lipid values also fall during acute illness, so a low LDL-C or HDL-C drawn during sepsis or an acute coronary event should be repeated after recovery. The panel is a sibling of the CMP and Thyroid Panel, since high cholesterol can reflect hypothyroidism, nephrotic syndrome or cholestasis.

When to Order:
  • Hypertriglyceridemia with abdominal pain: triglycerides ≥1,000 mg/dL as a possible cause of pancreatitis, with lipase
  • Suspected familial hypercholesterolemia: LDL-C ≥190 mg/dL, or premature ASCVD in a first-degree relative
  • Secondary causes of high LDL-C: suspected hypothyroidism, nephrotic syndrome or cholestasis
  • Monitoring lipid-lowering therapy: statins, ezetimibe, fibrates or omega-3 products
  • Wellness and cardiovascular screening: routine risk assessment in outpatient care

Measured

Total Cholesterol

Desirable: <200 mg/dL

Sum of all cholesterol in serum. Interpret with HDL-C and LDL-C; very high values (≥300 mg/dL) raise suspicion for familial hypercholesterolemia.

Learn More

HDL Cholesterol

Normal: M ≥40 | F ≥50 mg/dL

Carries cholesterol back to the liver. Low values track with high triglycerides, obesity and inactivity, and fall during acute illness.

Learn More

Triglycerides

Normal: <150 mg/dL

Fat carried by very-low-density and chylomicron particles. Levels ≥500 mg/dL are severe; ≥1,000 mg/dL carries high pancreatitis risk.

Learn More

Calculated

LDL Cholesterol

Optimal: <100 mg/dL

Main treatment target for statins. Calculated LDL-C is unreliable when triglycerides are high; a direct LDL-C is preferred in that case.

Learn More

Non-HDL Cholesterol

Desirable: <130 mg/dL

Total cholesterol minus HDL-C. Captures all atherogenic particles and does not need a calculation formula, so it stays valid when triglycerides are high.

Learn More

Reference Ranges & Critical Values
Adult lipid reference ranges and critical values
TestAdult Normal (conventional)SI UnitsCritical LowCritical HighNotes
Total cholesterol
<200 mg/dL desirable
<5.2 mmol/L
—
≥300 mg/dL
Rough FH flag; not a lab critical call
LDL cholesterol
<100 mg/dL optimal
<2.6 mmol/L
—
≥190 mg/dL
FH evaluation and high-intensity statin threshold; not a lab critical call
HDL cholesterol
M ≥40 | F ≥50 mg/dL
M ≥1.0 | F ≥1.3 mmol/L
—
—
Low is a risk marker, not a target
Triglycerides
<150 mg/dL normal
<1.7 mmol/L
—
≥1,000 mg/dL
Pancreatitis risk; urgent; lab-dependent
Non-HDL cholesterol
<130 mg/dL desirable
<3.4 mmol/L
—
—
Total minus HDL; goal by risk
Lab variation: Every lab, analyzer and assay sets its own intervals and critical-value list. Use your lab's reported interval and its critical-call policy.

Systematic Interpretation
  1. Specimen and fasting status: check for a turbid (lipemic) sample, recent meals, recent illness, and lipid-active drugs (propofol infusions, steroids, estrogen).
  2. Triglycerides: 150–199 mg/dL is borderline high and 200–499 mg/dL is high. ≥500 mg/dL is severe, and ≥1,000 mg/dL carries high pancreatitis risk and needs urgent treatment decisions.
  3. Non-HDL cholesterol: total cholesterol minus HDL-C. When triglycerides are high, make it your primary atherogenic marker.
  4. LDL cholesterol: when triglycerides are high, or the lab reports one, use a direct LDL-C. A calculated value is unreliable at high triglycerides.
  5. HDL cholesterol: low HDL-C (<40 mg/dL men, <50 mg/dL women) is a risk marker. On its own it is not a treatment target.
  6. Compare with the risk-based goal: the 2026 ACC/AHA dyslipidemia guideline sets LDL-C goals by the patient's ASCVD risk category. Look up the current numeric target for that category in the guideline tables. Don't rely on a single cutoff.
  7. Secondary causes: before you call it a primary disorder, rule out hypothyroidism, nephrotic syndrome, cholestasis, diabetes, and drugs such as corticosteroids and estrogen.
Non-HDL cholesterol
Total cholesterol − HDL-C

Normal: <130 mg/dL. No fasting and no triglyceride-based formula are needed.

Friedewald LDL-C (calculated)
LDL-C = Total cholesterol − HDL-C − (Triglycerides ÷ 5), all in mg/dL

Unreliable when triglycerides are ≥400 mg/dL. When the lab offers one, use a direct LDL-C or an alternative method such as Martin-Hopkins.

Worked Example: Total cholesterol 280 mg/dL, HDL-C 38 mg/dL (man), triglycerides 420 mg/dL. Non-HDL-C is 280 − 38 = 242 mg/dL, far above the 130 mg/dL desirable limit. The Friedewald LDL-C works out to 280 − 38 − 84 = 158 mg/dL. At 420 mg/dL, triglycerides make that number unreliable, so order a direct LDL-C. Still, 420 mg/dL sits in the high band (200–499 mg/dL), below the 500 mg/dL severe and 1,000 mg/dL pancreatitis-risk thresholds.

Patterns & Differential

One number rarely tells the story. The pattern does. The table lists the common ones and the next step for each.

PatternKey FindingsCommon CausesNext Step
Isolated high LDL-C
LDL-C high, triglycerides normal
Familial hypercholesterolemia, hypothyroidism, nephrotic syndrome, cholestasis
Ask about family history; check TSH, urine protein and liver tests
Isolated high triglycerides
Triglycerides ≥150 mg/dL, LDL-C near normal
Diabetes, obesity, alcohol, estrogen, pregnancy, corticosteroids
Check glucose or HbA1c and alcohol intake; treat per risk
Mixed high cholesterol and triglycerides
Both raised; low HDL-C common
Metabolic syndrome, familial combined hyperlipidemia, hypothyroidism
Use non-HDL-C as the target; check glucose and TSH
Very high triglycerides with pancreatitis
Triglycerides ≥1,000 mg/dL, abdominal pain, raised lipase
Genetic lipoprotein lipase disorders, uncontrolled diabetes, alcohol, drug-induced
Treat as pancreatitis; start triglyceride-lowering therapy per protocol
Low lipids in acute illness
LDL-C and HDL-C low during sepsis, trauma or acute coronary syndrome
Acute-phase response, malnutrition, severe liver disease
Repeat after recovery; do not treat the low value
Elevated lipoprotein(a)
Lp(a) raised, often with a family history of early ASCVD
Genetic; lifestyle changes have minimal effect
Measure once for risk assessment; the result does not change with lifestyle, so do not treat diet or exercise as the fix
Low LDL-C with statin therapy
LDL-C reduced on treatment
Expected drug effect, adherence, or a missed dose
Confirm adherence before changing the dose

Serial Testing & Kinetics

Lipids move over weeks to months, not minutes. The table shows each main analyte and when to repeat it.

AnalyteChanges WithTimingRepeat or Monitoring Target
LDL-C and HDL-C
Acute illness, sepsis, trauma, acute coronary syndrome
Fall during the acute phase
Repeat at least 3 weeks after recovery
Triglycerides
Meals, alcohol, insulin deficiency, propofol and other lipid infusions
Rise within hours of a meal or infusion
Repeat in the non-acute setting; use a fasting value when possible
Lipids on therapy
Statins, ezetimibe, fibrates, omega-3 products
Changes over weeks after a dose change
Repeat per the treating clinician's schedule

Critical Findings & Emergency Actions

Triglycerides ≥1,000 mg/dL with pancreatitis

Recognize: Look for epigastric pain, nausea or vomiting and raised lipase, with triglycerides ≥1,000 mg/dL (≥11.3 mmol/L). Treat it like any other pancreatitis. Lipid lowering is added on top.

  1. Protocol first (ED/ICU): NPO, analgesia and IV fluid resuscitation per local pancreatitis protocol and medical direction.
  2. Lower triglycerides: stop or hold causative agents where possible (propofol, IV lipid emulsion or TPN lipids, estrogen) and treat uncontrolled diabetes. Then IV insulin infusion with dextrose and glucose monitoring per protocol. High-alert (see insulin). Evidence for insulin infusion in this setting is limited, and practice is protocol- and center-dependent.
  3. Escalate: plasmapheresis is used at centers with that capability, and its evidence is limited; transfer early if not available. Confirm the decision with the medical director.
  4. Avoid: treating the lipid value alone. That is the trap. Fluid needs and pancreatitis complications come first.
Pitfall: Some indirect ion-selective electrode analyzers can read sodium falsely low in a lipemic sample. Before you treat a low sodium, get the lab to confirm it.

Prehospital & Transport Considerations

Point-of-Care Testing

Nothing point-of-care for lipids is standard in EMS, the ED or critical-care transport. Only laboratory analyzers run lipid panels.

MethodAnalytesSpecimenLimitations
Laboratory analyzer
Total cholesterol, HDL-C, triglycerides, LDL-C (direct or calculated)
Gold/green serum or plasma tube
Turnaround time; lipemia interferes with results

Interfacility Transfer & Handoff

  • Obtain: most recent lipid values with draw dates, and whether they were fasting.
  • Medications: statin, ezetimibe, fibrate or omega-3 products, and any recent dose changes.
  • Pending: lipase or glucose if pancreatitis is suspected; triglyceride-lowering therapy should be documented in the handoff.
  • En route: a lipid repeat is not needed during transport. Document any insulin infusion rate and glucose checks.

Scope Notes

  • Transport teams do not start lipid-lowering therapy. Any triglyceride-lowering treatment follows local protocols and medical direction.
  • A lipid value changes field or transport decisions only when the patient has pancreatitis or a triglyceride level high enough to need ICU care.

Special Populations

Pediatrics

Children's lipid ranges are not the adult ranges. Use the reporting lab's pediatric intervals. The NHLBI expert panel (2011) recommends routine screening once at 9 to 11 years and again at 17 to 21 years. An LDL-C of ≥190 mg/dL in a child warrants evaluation for familial hypercholesterolemia. Pediatric insulin dosing for triglyceride-lowering follows pediatric protocols: see weight-based dosing.

Pregnancy

Lipids climb in pregnancy, so a high value alone does not mean a disorder. In 2021 the FDA asked statin makers to remove the class-wide pregnancy contraindication, which makes each statin decision individual. Most patients, the FDA still advises, stop statins once they learn they are pregnant. Its 2021 communication also says breastfeeding is not recommended while taking a statin, and the treating clinician decides the plan.

Older Adults

In older or frail patients, a low LDL-C can mean malnutrition or illness, not a protective state. Read a low value in that context before you reassure the patient.

CKD and Nephrotic Syndrome

Nephrotic-range proteinuria pushes LDL-C and triglycerides up. Chronic kidney disease typically raises triglycerides and lowers HDL-C, and LDL-C is often normal. Before you blame a high lipid value on a primary disorder, check urine protein and renal function.

Specimen Collection & Interfering Factors
  • Tube: gold or green (serum or lithium heparin plasma). Tube color depends on the institution.
  • Fill and handling: fill to the line; mix gently and avoid hemolysis.
  • Order of draw (CLSI GP41): blood cultures, then light blue, then red or gold, then green, then lavender, then gray.
  • Fasting: a recent meal hits triglycerides hardest. Total cholesterol, HDL-C, LDL-C and non-HDL-C do not need a fast.
Error or InterferentEffect on ResultsPrevention
Lipemia (turbid sample)
Falsely low sodium on some indirect analyzers; interferes with some assays
Confirm with the lab; repeat if unexpected
Propofol or lipid emulsion infusion
Raises triglycerides systemically (exogenous fat)
Document the infusion, its rate and duration, and interpret TG in that context; draw away from the infusion line only to avoid contamination; repeat after the infusion stops if the result will change management
Non-fasting sample
Raises triglycerides; calculated (Friedewald) LDL-C reads falsely low as TG rises and is unreliable at TG ≥400 mg/dL
Repeat fasting if TG ≥400 mg/dL or the result will change management; use a direct LDL-C, a Martin-Hopkins estimate, or non-HDL-C when TG is high
Acute illness
Lowers LDL-C and HDL-C
Repeat after recovery
Drawing above an IV line
Dilution can lower all values
Draw below the IV or from the other arm
Hemolysis
Interferes with some assays
Avoid prolonged tourniquet and vigorous mixing

Clinical Pearls
Lipids do not diagnose ACS: troponin does. Draw the panel during an acute coronary event or sepsis and it reads low. Repeat it after recovery.
Use non-HDL-C when triglycerides are high: it needs no Friedewald formula. It counts every atherogenic particle.
Propofol raises triglycerides: in ICU patients on prolonged propofol, check triglycerides before you call a high value a primary disorder.
Ask about statins and missed doses: when LDL-C won't fall on therapy, adherence is usually the first answer, not a higher dose.
Pancreatitis with high triglycerides: in a patient with known hyperlipidemia, abdominal pain and vomiting mean you check lipase and triglycerides together.
Pitfall: Friedewald LDL-C is unreliable at triglycerides ≥400 mg/dL, and it can underestimate LDL-C. Order a direct LDL-C instead.
Pitfall (field): Don't hold transfer for a lipid result. Only the lab runs lipid testing, so the handoff should carry the latest values and statin history.

Related

References
  1. ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. https://doi.org/10.1016/j.jacc.2025.11.016
  2. Grundy SM, et al. 2018 AHA/ACC/multisociety guideline on the management of blood cholesterol. Circulation. 2019. https://doi.org/10.1161/CIR.0000000000000625
  3. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013. https://doi.org/10.1001/jama.2013.280532
  4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. https://doi.org/10.1093/clinchem/18.6.499
  5. Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy. Drug Safety Communication. July 20, 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy
  6. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert Panel Report: Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Pediatrics. 2011. https://doi.org/10.1542/peds.2009-2107C
  7. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO 2013 Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl. 2013;3(3):259–305.
  8. Clinical and Laboratory Standards Institute. Collection of Diagnostic Venous Blood Specimens; Approved Standard, 7th ed. (CLSI GP41). 2017.

Last updated Spotted something wrong? Report an error and include the page URL.

Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.